Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
NEWTOWN, Pa., April 26, 2017 -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Dr. Ramesh Kumar, President & CEO, will present an overview at PIONEERS 2017 presented by Joseph Gunnar & Co., LLC.
Presentation Details:
Date: Tuesday, May 2, 2017
Time: 8:30 am ET
Location: Mandarin Oriental Hotel, New York City
A recording of the presentation will be available on the Investor Page of Onconova’s website and will be active for 90 days following the event.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS). Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule agent, which blocks cellular signaling by targeting RAS effector pathways. Using a proprietary chemistry platform, Onconova has created a pipeline of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. Onconova has three product candidates in clinical trials and several active pre-clinical programs. Advanced clinical trials with our lead compound, rigosertib, are aimed at unmet medical needs of patients with MDS. For more information, please visit http://www.onconova.com.
GENERAL CONTACT: http://www.onconova.com/contact/ INVESTOR RELATIONS CONTACT: Lisa Sher, MBS Value Partners on behalf of Onconova Therapeutics [email protected] / (212) 750-5800
